litlas
Log inCreate account

Amita Patnaik

Active 2001–2025

122
Papers
32,996
Citations
78
h-index
115
i10-index

Citations

Citations per year for Amita Patnaik1998: 1 citations2000: 1 citations2001: 2 citations2003: 8 citations2004: 33 citations2005: 72 citations2006: 84 citations2007: 114 citations2008: 107 citations2009: 121 citations2010: 107 citations2011: 84 citations2012: 107 citations2013: 175 citations2014: 302 citations2015: 557 citations2016: 760 citations2017: 858 citations2018: 750 citations2019: 1,835 citations2020: 2,000 citations2021: 1,704 citations2022: 1,290 citations2023: 891 citations2024: 1,207 citations2025: 626 citations2026: 20 citations1999: no citations, so this year is not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,154 citing papers, 28.3% of this breakdownChina: 2,608 citing papers, 14.3% of this breakdownItaly: 914 citing papers, 5% of this breakdownUnited Kingdom: 891 citing papers, 4.9% of this breakdownGermany: 843 citing papers, 4.6% of this breakdownFrance: 812 citing papers, 4.5% of this breakdownJapan: 646 citing papers, 3.6% of this breakdownSpain: 561 citing papers, 3.1% of this breakdownCanada: 542 citing papers, 3% of this breakdownAustralia: 532 citing papers, 2.9% of this breakdownNetherlands: 482 citing papers, 2.7% of this breakdownSouth Korea: 445 citing papers, 2.4% of this breakdown
0%28.3%Other 20.7%

Institutions

Fields

  • Medicine68%
  • Biochemistry, Genetics and Molecular Biology19.2%
  • Immunology and Microbiology9.4%
  • Engineering0.9%
  • Materials Science0.7%
  • Neuroscience0.3%
  • Other1.5%

Topics

  • Cancer Immunotherapy and Biomarkers16.5%
  • Immunotherapy and Immune Responses6%
  • CAR-T cell therapy research4.8%
  • Lung Cancer Treatments and Mutations3.9%
  • Immune Cell Function and Interaction3.2%
  • Immune cells in cancer2.4%
  • Other63.2%

Coauthors

All papers

Open in search
  1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    Authors: Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi - New England Journal of Medicine 2015 cited by 6,228

  2. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Authors: Edward B. Garon, Matthew D. Hellmann, Naiyer A. Rizvi, Enric Carcereny, Natasha B. Leighl, Myung-Ju Ahn, Joseph Paul Eder, Ani S. Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew Gubens, Suresh S. Ramalingam, Enriqueta Felip, Jonathan W. Goldman, Cathie Scalzo, Erin Jensen, Debra A. Kush, Rina Hui - Journal of Clinical Oncology 2019 cited by 1,185

  3. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

    Authors: Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, Sumit Shah, Sreenivasa R Chandana, Drew Rasco, A. Dimitrios Colevas, Timothy J. O’Rourke, Sujata Narayanan, Kyriakos P. Papadopoulos, George A. Fisher, Víctor M. Villalobos, Susan Prohaska, Maureen Howard, Muralidhar Beeram, Mark P. Chao, Balaji Agoram, James Y. Chen, Jie Huang, Matthew Axt, Jie Liu, Jens-Peter Volkmer, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Dana Supan, Heather A. Wakelee, Rhonda Aoki, Mark D. Pegram, Sukhmani K. Padda - Journal of Clinical Oncology 2019 cited by 590

  4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

    Authors: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen‐Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Mitchell, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Qi Zhao, E. Jensen, S. Ahsan, Nageatte Ibrahim, Antoni Ribas - Annals of Oncology 2019 cited by 944

  5. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Authors: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss‐Schaap, Alain P. Algazi, Christine Mateus, Peter D. Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot Ebbinghaus, Xiaoyun Li, Sunyu Kang, Antoni Ribas - New England Journal of Medicine 2013 cited by 3,395

  6. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

    Authors: Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton, Do‐Youn Oh, Diana L. Hanna, Yoon‐Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee, Lisle Nabell, Sun Young Rha, José Mayordomo, Anthony B. El-Khoueiry, Shubham Pant, Kanwal Pratap Singh Raghav, Jin Won Kim, Amita Patnaik, Todd Gray, R. H. Davies, Mark A. Ozog, Joseph Woolery, Keun‐Wook Lee - The Lancet Oncology 2022 cited by 182

  7. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Authors: Antoni Ribas, Omid Hamid, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Richard Kefford, Anthony M. Joshua, Amita Patnaik, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Peter Hersey, Roxana Dronca, Richard W. Joseph, Hassane M. Zarour, Bartosz Chmielowski, Donald P. Lawrence, Alain P. Algazi, Naiyer A. Rizvi, Brianna Hoffner, Christine Mateus, Kevin Gergich, Jill A. Lindia, Maxine Giannotti, Xiaoyun Li, Scot Ebbinghaus, Soonmo Peter Kang, Caroline Robert - JAMA 2016 cited by 1,062

  8. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Authors: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 cited by 1,392

  9. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Authors: Amita Patnaik, Soonmo Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss‐Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, M. Lehnert, Robert Iannone, Anthony W. Tolcher - Clinical Cancer Research 2015 cited by 794

  10. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Authors: Adil Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard W. Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Charlotte Roach, Grant Toland, Jared Lunceford, Xiaoyun Li, Kenneth Emancipator, Marisa Dolled‐Filhart, Sunyu Kang, Scot Ebbinghaus, Omid Hamid - Journal of Clinical Oncology 2016 cited by 678

  11. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    Authors: Caroline Robert, Antoni Ribas, Jedd D. Wolchok, F. Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S. Weber, Anthony M. Joshua, Wen-Jen Hwu, Tara C. Gangadhar, Amita Patnaik, Roxana Dronca, Hassane M. Zarour, Richard W. Joseph, Peter D. Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A. Postow, Kevin Gergich, Jeroen Elassaiss‐Schaap, Xiaoyun Li, Robert Iannone, Scot Ebbinghaus, Soonmo Peter Kang, Adil Daud - The Lancet 2014 cited by 1,761

  12. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

    Authors: James J. Harding, Víctor Moreno, Yung‐Jue Bang, Min Hee Hong, Amita Patnaik, José Trigo, Anna M. Szpurka, Noboru Yamamoto, Toshihiko Doi, Siqing Fu, Boris Calderón, Nieves Vélez de Mendizábal, Emiliano Calvo, Danni Yu, Leena Gandhi, Zhuqing Tina Liu, Violeta Régnier Galvão, Ching Ching Leow, Maria J. de Miguel - Clinical Cancer Research 2021 cited by 159

  13. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Authors: Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, John Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martínez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro - Cancer Discovery 2016 cited by 760

  14. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

    Authors: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard W. Joseph, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Jin Zhang, James R. Anderson, Scott J. Diede, Scot Ebbinghaus, F. Stephen Hodi - Journal of Clinical Oncology 2017 cited by 482

  15. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

    Authors: David S. Hong, Michael A. Postow, Bartosz Chmielowski, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen, Geoffrey I. Shapiro, Conor Steuer, Martin Gutierrez, Heather Yeckes-Rodin, Robert Ilaria, Brenda O’Connell, Joanna Peng, Guangbin Peng, Nora Zizlsperger, Anthony W. Tolcher, Jedd D. Wolchok - Clinical Cancer Research 2023 cited by 78

  16. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

    Authors: Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou, David Olmos, George Wang, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Shobha Seetharam, Johann S. de Bono, Anthony W. Tolcher - Cancer Chemotherapy and Pharmacology 2013 cited by 262

  17. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

    Authors: Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, Soonmo Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar - Clinical Cancer Research 2018 cited by 309

  18. Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

    Authors: Yonina R. Murciano‐Goroff, Rebecca S. Heist, Yasutoshi Kuboki, Takafumi Koyama, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Amita Patnaik, Toshio Shimizu, Alexander I. Spira, Misako Nagasaka, Ji‐Youn Han, Wade T. Iams, Dustin A. Deming, Justin Call, Philippe A. Cassier, Sae‐Won Han, Quincy Siu-chung Chu, Rasha Cosman, Gregory A. Durm, Timothy F. Burns, Melinda D. Willard, Shiyao Liu, Sophie Callies, Arjun Vasant Balar, Joshua K. Sabari - Cancer Research 2023 cited by 37

  19. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

    Authors: Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan - Annals of Oncology 2016 cited by 236

  20. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

    Authors: Renata Ferrarotto, Yoshitsugu Mitani, Lixia Diao, Irene Guijarro, Jing Wang, Patrick A. Zweidler‐McKay, Diana Bell, William N. William, Bonnie S. Glisson, Michael J. Wick, Ann M. Kapoun, Amita Patnaik, Gail Eckhardt, Pamela N. Münster, Leonardo Faoro, Jakob Dupont, J. Jack Lee, P. Andrew Futreal, Adel K. El‐Naggar, John V. Heymach - Journal of Clinical Oncology 2017 cited by 245

  21. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

    Authors: Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih‐Hsin Yang, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Mehmet Altan, Shadia I. Jalal, Amit Panwalkar, Matthew A. Gubens, Lecia V. Sequist, Sanatan Saraf, Bin Zhao, Bilal Piperdi, Corey J. Langer - Journal of Thoracic Oncology 2020 cited by 183

  22. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

    Authors: James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist, Chien-Liang Wu, Vassiliki A. Papadimitrakopoulou, Wu‐Chou Su, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Amita Patnaik - Journal of Thoracic Oncology 2018 cited by 183

  23. Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.

    Authors: Antoine Hollebecque, Yasutoshi Kuboki, Yonina R. Murciano‐Goroff, Rona Yaeger, Philippe A. Cassier, Rebecca S. Heist, Yutaka Fujiwara, Dustin A. Deming, Natraj Reddy Ammakkanavar, Amita Patnaik, Toshio Shimizu, Justin Call, Sae‐Won Han, Aaron Alan Fink, Aaron Chen, Melinda D. Willard, Arjun Vasant Balar, Takafumi Koyama - Journal of Clinical Oncology 2024 cited by 31

  24. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

    Authors: Rina Hui, Edward B. Garon, J.W. Goldman, Natasha B. Leighl, Matthew D. Hellmann, Amita Patnaik, Leena Gandhi, Joseph P. Eder, Myung‐Ju Ahn, Leora Horn, Enriqueta Felip, Enric Carcereny, Reshma Rangwala, Gregory M. Lubiniecki, J. Zhang, Kenneth Emancipator, Charlotte Roach, Naiyer A. Rizvi - Annals of Oncology 2017 cited by 235